| Black Hawk-grundy Mental Health Center Inc. | |
|
3251 W 9th St Waterloo IA 50702-5310 | |
| (319) 234-2893 | |
| (319) 234-0354 |
| Full Name | Black Hawk-grundy Mental Health Center Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 3251 W 9th St, Waterloo, Iowa |
| Authorized Official Name and Position | Thomas Charles Eachus (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 3192342893 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Black Hawk-grundy Mental Health Center Inc. 3251 W 9th St Waterloo IA 50702-5310 Ph: (319) 234-2893 | Black Hawk-grundy Mental Health Center Inc. 3251 W 9th St Waterloo IA 50702-5310 Ph: (319) 234-2893 |
| NPI Number | 1316944598 |
|---|---|
| Provider Enumeration Date | 07/05/2005 |
| Last Update Date | 06/19/2017 |
| Medicare PECOS PAC ID | 1850280363 |
|---|---|
| Medicare Enrollment ID | O20040312000767 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316944598 | NPI | - | NPPES |
| 0074435 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0801X | Clinic/center - Mental Health (including Community Mental Health Center) | (* (Not Available)) | Primary |
| Provider Name | Joyce M Andresen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1538314018 PECOS PAC ID: 9739236027 Enrollment ID: I20090402000024 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Connie L Popenhagen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1669662854 PECOS PAC ID: 3678611258 Enrollment ID: I20091119000344 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Patricia A Nelson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1417037086 PECOS PAC ID: 1052436425 Enrollment ID: I20100909000413 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Thomas C Eachus |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1518048537 PECOS PAC ID: 6002705514 Enrollment ID: I20100909000447 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Jamey L Gregersen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164823092 PECOS PAC ID: 1355561747 Enrollment ID: I20141007001731 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Donna R Dobson Tobin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245227099 PECOS PAC ID: 6103842968 Enrollment ID: I20150407001355 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Melissa S Adams |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1164872735 PECOS PAC ID: 3476816422 Enrollment ID: I20180404002467 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Nicole M Delagardelle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255823506 PECOS PAC ID: 5991053183 Enrollment ID: I20180803001777 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Tenaea M Jeppeson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043703887 PECOS PAC ID: 7517216187 Enrollment ID: I20180815003565 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Alyssa K Fruchtenicht |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1639511710 PECOS PAC ID: 5799034013 Enrollment ID: I20180821000323 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Stephanie Anne Giesler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750845954 PECOS PAC ID: 3274860754 Enrollment ID: I20190806002737 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Emily Swartley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417523192 PECOS PAC ID: 8820490972 Enrollment ID: I20210712002625 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Kathleen Holden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124692553 PECOS PAC ID: 8325441462 Enrollment ID: I20210727001004 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Kama Sarah Ausborn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669056123 PECOS PAC ID: 9133523517 Enrollment ID: I20210810003396 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Manraj Padda |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1376020933 PECOS PAC ID: 4082965405 Enrollment ID: I20220628000304 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
| Provider Name | Abby Irene Kolthoff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184056822 PECOS PAC ID: 1254796881 Enrollment ID: I20230503001497 |
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
News Archive
Mylan Inc. today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate).
In today's fast-paced health care environment, it is critical that hospitals keep their staff updated on using the latest imaging technology available. Currently, most facilities receive the majority of their diagnostic imaging equipment training when a new system is delivered. Toshiba America Medical Systems, Inc. recognizes the importance of maintaining that training edge and now is providing customers with an option – Performance Plus.
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial.
Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.
› Verified 2 days ago
New Start Behavioral Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 212 E 4th Street,, Waterloo, IA 50703 Phone: 319-493-5120 | |
Cedar Valley Center For Expressive Arts Therapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 905 Sycamore St, Waterloo, IA 50703 Phone: 319-888-1022 | |
Veridian Fiscal Solutions Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 233 Fisher Dr, Waterloo, IA 50701 Phone: 855-828-0775 | |
Veridian Fiscal Solutions Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 233 Fisher Dr, Waterloo, IA 50701 Phone: 855-828-0775 | |
Change Behavioral Health, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 Sycamore St Ste 623, Waterloo, IA 50703 Phone: 319-233-0323 Fax: 319-233-5923 | |
Hope Tree Counseling Services Inc. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1420 W Donald St, Waterloo, IA 50703 Phone: 319-232-4673 | |
Pathways Behavioral Services, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 905 Franklin St, Waterloo, IA 50703 Phone: 319-272-4300 |